Standard BioTools Reports $127.1M Q1 Net Income, Strong Cash Position, and Improved Operations

summarizeSummary

Standard BioTools reported a Q1 2026 net income of $127.1 million and a strong cash balance of $550 million, reflecting the successful divestiture of its SomaScan business and significant operational improvements.

check_boxKey Events · Earnings and Guidance · LAB

• Reports $127.1 Million Q1 Net Income

  The company reported a net income of $127.1 million for Q1 2026, a significant turnaround from a net loss of $26.0 million in the prior year, largely due to the gain on the sale of its SomaScan business.

• Achieves Strong Cash Position

  Cash and investments reached approximately $550 million as of March 31, 2026, providing substantial capital for future strategic initiatives and inorganic growth.

• Significant Operational Improvement

  Operating loss decreased by 54% and adjusted EBITDA improved by 78% year-over-year, demonstrating effective cost savings and progress towards profitability.

• Maintains Full Year 2026 Revenue Outlook

  The company reiterated its full-year 2026 revenue guidance in the range of $80 million to $85 million.

auto_awesomeAnalysis · LAB · Industrial Applications And Services

Standard BioTools Inc. reported a significant financial turnaround in Q1 2026, driven by a substantial net income of $127.1 million, primarily from the divestiture of its SomaScan business. This filing confirms the successful execution of the company's strategic initiatives, resulting in a robust cash and investments balance of approximately $550 million. The company also demonstrated strong operational improvements, with a 54% reduction in operating loss and a 78% improvement in adjusted EBITDA year-over-year, reinforcing its path to profitability. This strong financial position provides substantial flexibility for future inorganic growth strategies.